ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)

A Phase III Double-Blind, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With PNEUMOVAX™ 23 in Subjects 60 Years of Age and Older

The purpose of this study is to determine whether Zoster Vaccine Live and Pneumococcal Vaccine, polyvalent are as well tolerated and immunogenic when the vaccines are given together (in different body sites), as when they are given alone, in adults 60 years of age and older.

Inclusion Criteria:

• 60 years of age or older
• Stable underlying conditions
• Postmenopausal if female
• Afebrile

Exclusion Criteria:

• Previously vaccinated with either vaccine
• Immune deficiency
• History of allergy to components in either vaccine
• Concomitant antiviral therapy